Intracranial Hematoma Drug Market Report 2026

The intracranial hematoma drug market size has grown strongly in recent years. It will grow from $1.75 billion in 2025 to $1.92 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to rising incidence of traumatic brain injuries, limited availability of advanced neurocritical care drugs, growing hospital admissions for stroke and hemorrhage cases, increased adoption of osmotic therapy drugs, expansion of emergency care infrastructure.

The intracranial hematoma drug market size is expected to see strong growth in the next few years. It will grow to $2.79 billion by 2030 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to advancement in neuroprotective drug development, integration of ai-based neurological monitoring systems, increasing demand for targeted intracranial pressure management therapies, growth in precision medicine for brain disorders, rising investment in neurocritical care research. Major trends in the forecast period include ai-driven neurocritical care decision support systems, precision drug delivery systems for intracranial pressure management, real-time brain imaging analytics integration in emergency care, smart ICU monitoring for neurotrauma patients, cloud-based neurological patient data management platforms.

The rising incidence of traumatic brain injuries is expected to propel the growth of the intracranial hematoma drug market going forward. Traumatic brain injuries (TBIs) are disruptions in normal brain function caused by a bump, blow, jolt to the head, or a penetrating head injury. The growing prevalence of TBIs is largely driven by an aging population, as older adults are more susceptible to falls, leading to a higher rate of severe head injuries that require medical intervention. The increasing occurrence of traumatic brain injuries further amplifies the demand for intracranial hematoma drugs targeting intracranial hematomas, as bleeding within the skull remains one of the most critical and life-threatening consequences of such injuries. For instance, in September 2025, according to the South Dakota Department of Health, a US-based government health agency, TBI-related deaths in the state increased from 241 in 2023 to 267 in 2024, reflecting an 11% rise. Therefore, the rising incidence of traumatic brain injuries is driving the growth of the intracranial hematoma drug market.

The increasing healthcare expenditure is expected to propel the growth of the intracranial hematoma drug market going forward. Healthcare expenditure refers to the total spending on healthcare goods and services, including hospital care, pharmaceuticals, and preventive services, by governments, private organizations, and individuals. The rise in healthcare expenditure is attributed to increasing government funding, which strengthens healthcare infrastructure and expands access to advanced medical treatments. Intracranial hematoma drugs help optimize healthcare spending by enabling effective management of brain hemorrhage, improving survival rates, and reducing long-term treatment costs through timely intervention. For instance, in April 2025, according to the Office for National Statistics, a UK-based government statistics authority, healthcare expenditure reached £252 billion ($289.89 billion) in 2023, reflecting a 5.9% nominal increase compared to 2022. Therefore, the increasing healthcare expenditure is propelling the growth of the intracranial hematoma drug market.

Leading companies operating in the intracranial hematoma drug market are focusing on developing innovative therapies such as ready-to-use injectables to address unmet clinical needs, improve patient survival rates, and enable faster emergency intervention. Ready-to-use injectables are sterile, pre-formulated medications designed for immediate administration without requiring dilution or reconstitution. For example, in April 2023, Alveron Pharma, a Netherlands-based developer of a unique coagulation platform technology, initiated a Phase 1 clinical trial of its novel drug candidate OKL-1111 for the treatment of intracranial hemorrhage. The drug is designed as a rapid, first-line therapy with a universal mode of action that does not require identification of the specific anticoagulant, significantly reducing treatment delays. It is being developed as a ready-to-use injectable solution, eliminating time-consuming preparation steps, and is intended to quickly reverse the effects of anticoagulants and platelet inhibitors to prevent hematoma expansion. Additionally, preclinical data indicate a low risk of thrombotic complications, enabling faster administration and potential use even in emergency settings, such as ambulances, thereby improving overall patient outcomes.

Major companies operating in the intracranial hematoma drug market are Johnson & Johnson Services Inc., Pfizer Inc., Bayer AG, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Baxter International Inc., Grifols S. A., Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Limited, Octapharma AG, Amneal Pharmaceuticals Inc., Zydus Lifesciences Limited, CSL Behring LLC, Otsuka Pharmaceutical Co. Ltd., Alveron Pharma AB, Acticor Biotech SA, Aegis Lifesciences Private Limited, Acasti Pharma Inc.

North America was the largest region in the intracranial hematoma drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intracranial hematoma drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the intracranial hematoma drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intracranial hematoma drug market consists of sales of mannitol injection, hypertonic saline solution, tranexamic acid injection, prothrombin complex concentrate, fresh frozen plasma, and recombinant factor VIIa injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.